Article Details

CureVac, GSK's Bivalent MRNA Vaccine Candidate Highly Effective Against COVID-19 Variants

Retrieved on: 2022-04-21 13:18:11

Tags for this article:

Click the tags to see associated articles and topics

CureVac, GSK's Bivalent MRNA Vaccine Candidate Highly Effective Against COVID-19 Variants. View article details on hiswai:

Excerpt

Despite containing only half the dose per variant-mRNA, the combined Beta/Delta candidate elicited neutralizing antibody titers fully comparable ...

Article found on: www.rttnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up